MCID: PRT096
MIFTS: 54

Peritoneal Mesothelioma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Peritoneal Mesothelioma

MalaCards integrated aliases for Peritoneal Mesothelioma:

Name: Peritoneal Mesothelioma 12 15 73
Malignant Mesothelioma of Peritoneum 12 73
Advanced Malignant Mesothelioma of Peritoneum 12
Advanced Malignant Peritoneal Mesothelioma 12
Advanced Peritoneal Malignant Mesothelioma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1788
ICD10 33 C45.1
NCIt 50 C8704 C9350
SNOMED-CT 68 109853004 187806007

Summaries for Peritoneal Mesothelioma

Disease Ontology : 12 A peritoneum cancer that develops from cells of the mesothelium and is located in the peritoneum.

MalaCards based summary : Peritoneal Mesothelioma, also known as malignant mesothelioma of peritoneum, is related to malignant peritoneal mesothelioma and mucinous adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Peritoneal Mesothelioma is BAP1 (BRCA1 Associated Protein 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include the peritoneum, colon and t cells, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This... more...

Related Diseases for Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 malignant peritoneal mesothelioma 32.8 BAP1 CDKN2A EGFR MUC1 NF2
2 mucinous adenocarcinoma 30.2 CDKN2A EGFR MUC1
3 neurofibroma 30.0 CDKN2A MUC1 NF2
4 malignant peripheral nerve sheath tumor 29.5 CDKN2A EGFR MUC1 NF2
5 benign multicystic peritoneal mesothelioma 12.5
6 benign peritoneal mesothelioma 12.3
7 peritoneal cystic mesothelioma 11.5
8 peritonitis 11.0
9 lymphohistiocytoid mesothelioma 10.8 CDKN2A THBD
10 hepatoid adenocarcinoma 10.8 EGFR MUC1
11 anaplastic oligodendroglioma 10.8 CDKN2A EGFR
12 mucinous bronchioloalveolar adenocarcinoma 10.7 CDKN2A MUC1
13 cholangiolocellular carcinoma 10.7 CDKN2A MUC1
14 cervical adenosquamous carcinoma 10.7 CDKN2A EGFR
15 pleomorphic liposarcoma 10.7 CDKN2A MUC1
16 ischemic fasciitis 10.7 CDKN2A MUC1
17 fibrous meningioma 10.7 MUC1 NF2
18 well-differentiated liposarcoma 10.7 CDKN2A MUC1
19 transitional meningioma 10.7 MUC1 NF2
20 dedifferentiated liposarcoma 10.7 CDKN2A MUC1
21 chordoid glioma 10.6 MUC1 NF2
22 optic nerve sheath meningioma 10.6 CDKN2A NF2
23 oropharynx cancer 10.6 CDKN2A EGFR
24 plasmablastic lymphoma 10.6 CDKN2A MUC1
25 atypical neurofibroma 10.6 CDKN2A NF2
26 meningeal melanocytoma 10.6 CDKN2A MUC1
27 anaplastic ependymoma 10.6 MUC1 NF2
28 syringoma 10.6 ESR1 MUC1
29 basaloid squamous cell carcinoma 10.6 CDKN2A EGFR
30 intracystic papillary adenoma 10.6 EGFR PGR
31 endocervical carcinoma 10.6 CDKN2A ESR1
32 progesterone-receptor negative breast cancer 10.6 EGFR PGR
33 breast mucoepidermoid carcinoma 10.6 MUC1 PGR
34 malignant mixed mullerian tumor 10.5 MUC1 PGR
35 clear cell meningioma 10.5 MUC1 PGR
36 vulvar dystrophy 10.5 CDKN2A PGR
37 breast squamous cell carcinoma 10.5 EGFR PGR
38 biliary tract neoplasm 10.5 CDKN2A MUC1
39 bizarre leiomyoma 10.5 CDKN2A PGR
40 microglandular adenosis 10.5 EGFR PGR
41 lobular neoplasia 10.5 ESR1 MUC1
42 malignant epithelial mesothelioma 10.5 THBD WT1
43 perivascular epithelioid cell tumor 10.5 MUC1 PGR
44 lung meningioma 10.4 NF2 PGR
45 olfactory groove meningioma 10.4 NF2 PGR
46 fallopian tube squamous cell carcinoma 10.4 CDKN2A WT1
47 chordoma 10.4 CDKN2A EGFR MUC1
48 adenomatoid tumor 10.4 THBD WT1
49 vulvar syringoma 10.4 ESR1 PGR
50 lung leiomyoma 10.4 ESR1 PGR

Graphical network of the top 20 diseases related to Peritoneal Mesothelioma:



Diseases related to Peritoneal Mesothelioma

Symptoms & Phenotypes for Peritoneal Mesothelioma

UMLS symptoms related to Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.83 EGFR
2 Decreased viability GR00221-A-1 9.83 LATS2 CDKN2A EGFR ESR1
3 Decreased viability GR00221-A-2 9.83 LATS2 ESR1
4 Decreased viability GR00221-A-3 9.83 CDKN2A
5 Decreased viability GR00221-A-4 9.83 ESR1 LATS2 CDKN2A EGFR
6 Decreased viability GR00402-S-2 9.83 LATS2 CDKN2A EGFR ESR1

MGI Mouse Phenotypes related to Peritoneal Mesothelioma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 THBD ESR1 PGR LATS2 WT1 CDKN2A
2 cellular MP:0005384 10.21 LATS2 ESR1 PGR THBD WT1 CDKN2A
3 embryo MP:0005380 10.2 THBD NF2 ESR1 PGR LATS2 WT1
4 homeostasis/metabolism MP:0005376 10.19 NF2 ESR1 PGR LATS2 THBD WT1
5 endocrine/exocrine gland MP:0005379 10.14 NF2 ESR1 PGR LATS2 WT1 CDKN2A
6 growth/size/body region MP:0005378 10.13 LATS2 NF2 ESR1 WT1 THBD EGFR
7 immune system MP:0005387 10.13 NF2 ESR1 PGR THBD WT1 CDKN2A
8 hematopoietic system MP:0005397 10.11 PGR ESR1 WT1 THBD EGFR CDKN2A
9 mortality/aging MP:0010768 10.1 LATS2 NF2 ESR1 PGR THBD WT1
10 integument MP:0010771 10 NF2 ESR1 PGR THBD EGFR CDKN2A
11 liver/biliary system MP:0005370 9.98 THBD NF2 ESR1 LATS2 WT1 CDKN2A
12 muscle MP:0005369 9.97 ESR1 PGR LATS2 WT1 CDKN2A BAP1
13 neoplasm MP:0002006 9.87 NF2 ESR1 PGR WT1 CDKN2A BAP1
14 no phenotypic analysis MP:0003012 9.8 ESR1 PGR LATS2 WT1 CDKN2A BAP1
15 normal MP:0002873 9.7 LATS2 ESR1 PGR THBD WT1 EGFR
16 reproductive system MP:0005389 9.56 NF2 ESR1 PGR THBD WT1 CDKN2A
17 respiratory system MP:0005388 9.17 NF2 ESR1 THBD WT1 CDKN2A BAP1

Drugs & Therapeutics for Peritoneal Mesothelioma

Drugs for Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Doxil Approved June 1999 Phase 3,Phase 2 31703
3 Ranpirnase Investigational Phase 3 196488-72-9
4 Topoisomerase Inhibitors Phase 3,Phase 2
5 Anti-Bacterial Agents Phase 3,Phase 2
6 Antibiotics, Antitubercular Phase 3,Phase 2
7
Gemcitabine Approved Phase 2 95058-81-4 60750
8
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
9
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
10
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
11
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
12
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
13
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
14
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
15
Promethazine Approved, Investigational Phase 2 60-87-7 4927
16
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
17
Fluorouracil Approved Phase 2 51-21-8 3385
18
Pancrelipase Approved, Investigational Phase 2 53608-75-6
19
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
20
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
21
Bevacizumab Approved, Investigational Phase 2 216974-75-3
22
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
23
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
24
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
25
Pembrolizumab Approved Phase 2 1374853-91-4
26
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
28
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
29
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
30 interferons Phase 2,Phase 1
31 Alkylating Agents Phase 2,Phase 1
32 Mitomycins Phase 2
33 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
34 Antibodies Phase 2,Phase 1
35 Immunoglobulins Phase 2,Phase 1
36 Antibodies, Monoclonal Phase 2,Phase 1
37 Immunosuppressive Agents Phase 2,Phase 1
38 Anti-Infective Agents Phase 2,Phase 1
39 Interferon-gamma Phase 2
40 Antimetabolites Phase 2
41 Antiviral Agents Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 2
43 Ranitidine bismuth citrate Phase 2
44 pancreatin Phase 2
45
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
46 Folic Acid Antagonists Phase 2,Phase 1
47 Albumin-Bound Paclitaxel Phase 2,Phase 1
48 Cortisol succinate Phase 2
49 Hydrocortisone 17-butyrate 21-propionate Phase 2
50 Hydrocortisone acetate Phase 2

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
4 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
5 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
6 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2 erlotinib hydrochloride
7 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
8 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed NCT01160458 Phase 2 IMC-A12
9 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
10 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Recruiting NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
11 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT02588781 Phase 2 Pemetrexed
12 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
13 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
14 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
15 Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting NCT02399371 Phase 2
16 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Active, not recruiting NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
17 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2
18 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1 Tremelimumab;MEDI4736
19 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
20 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Recruiting NCT03436732 Phase 1 LMB-100;SEL-110
21 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
22 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Active, not recruiting NCT02029690 Phase 1 ADI-PEG 20
23 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1 BAY94-9343;BAY94-9343 (Expansion);BAY94-9343 (1.8 mg/kg);BAY94-9343 (2.2 mg/kg)
24 CAR T Cells in Mesothelin Expressing Cancers Active, not recruiting NCT03054298 Phase 1
25 Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Not yet recruiting NCT03546426 Phase 1 Pembrolizumab;Interleukin-2
26 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
27 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
28 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Sur Recruiting NCT01416714
29 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
30 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
31 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
32 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Peritoneal Mesothelioma

Genetic Tests for Peritoneal Mesothelioma

Anatomical Context for Peritoneal Mesothelioma

The Foundational Model of Anatomy Ontology organs/tissues related to Peritoneal Mesothelioma:

19
The Peritoneum

MalaCards organs/tissues related to Peritoneal Mesothelioma:

41
Colon, T Cells, Lung, Pancreas, Lymph Node, Ovary, Testis

Publications for Peritoneal Mesothelioma

Articles related to Peritoneal Mesothelioma:

(show top 50) (show all 401)
# Title Authors Year
1
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. ( 29503128 )
2018
2
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. ( 29797583 )
2018
3
Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. ( 29431036 )
2018
4
Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases. ( 29048219 )
2018
5
Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. ( 29721724 )
2018
6
Benign multicystic peritoneal mesothelioma treated with laparoendoscopic single site surgery: a case report and review of the literature. ( 29372166 )
2018
7
The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. ( 29651664 )
2018
8
Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases. ( 29915796 )
2018
9
Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. ( 29260418 )
2018
10
Malignant Peritoneal Mesothelioma in the setting of a Ventriculo-Peritoneal Shunt: A novel clinical presentation. ( 29899672 )
2018
11
Malignant peritoneal mesothelioma in patients with endometriosis. ( 29794065 )
2018
12
Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites. ( 29577057 )
2018
13
Analysis of prognostic factors of patients with malignant peritoneal mesothelioma. ( 29506546 )
2018
14
Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma. ( 29423664 )
2018
15
Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study. ( 29978366 )
2018
16
Prognostic Significance of Blood, Serum, and Ascites Parameters in Patients with Malignant Peritoneal Mesothelioma or Peritoneal Carcinomatosis. ( 29643915 )
2018
17
Malignant peritoneal mesothelioma: a review. ( 28706904 )
2017
18
Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. ( 29184697 )
2017
19
Remote Recurrence of Benign Multicystic Peritoneal Mesothelioma. ( 28733062 )
2017
20
Reproducibility for histologic parameters in peritoneal mesothelioma. ( 28712777 )
2017
21
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. ( 28877056 )
2017
22
Malignant peritoneal mesothelioma - a rare cause of laparotomy. ( 28702106 )
2017
23
A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29019584 )
2017
24
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation. ( 28469343 )
2017
25
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. ( 28100259 )
2017
26
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% ofA Malignant Peritoneal Mesotheliomas. ( 28034829 )
2017
27
A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis. ( 28646342 )
2017
28
Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array. ( 28829357 )
2017
29
Multicystic peritoneal mesothelioma: A short review. ( 28528021 )
2017
30
miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. ( 28716051 )
2017
31
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. ( 28189456 )
2017
32
Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy. ( 29027138 )
2017
33
Benign Multicystic Peritoneal Mesothelioma: A Rare Condition in an Uncommon Gender. ( 28607791 )
2017
34
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. ( 28761723 )
2017
35
Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma. ( 28215643 )
2017
36
Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. ( 28830230 )
2017
37
Unusual presentation of a late-onset recurrence of malignant peritoneal mesothelioma. ( 28264807 )
2017
38
Presentation of a malignant peritoneal mesothelioma in the forma of rough hepatic calcifications. ( 28480727 )
2017
39
Epidemiology of malignant peritoneal mesothelioma: A population-based study. ( 29080447 )
2017
40
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. ( 28910456 )
2017
41
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. ( 28123552 )
2017
42
Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. ( 28540826 )
2017
43
A Rare Case of Biphasic Malignant Peritoneal Mesothelioma with Refractory Ascites. ( 28381756 )
2017
44
Diffuse peritoneal mesothelioma: A case series of 62 patients including paraoccupational exposures to chrysotile asbestos. ( 28940402 )
2017
45
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. ( 28849389 )
2017
46
Erratum: A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29267565 )
2017
47
Current management strategies for peritoneal mesothelioma. ( 28664790 )
2017
48
Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. ( 28324285 )
2017
49
Diagnostic Dilemma: Primary Peritoneal Mesothelioma With Para-Occupational Asbestos Exposure. ( 29244982 )
2017
50
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. ( 28594258 )
2017

Variations for Peritoneal Mesothelioma

Expression for Peritoneal Mesothelioma

Search GEO for disease gene expression data for Peritoneal Mesothelioma.

Pathways for Peritoneal Mesothelioma

GO Terms for Peritoneal Mesothelioma

Cellular components related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.65 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2
2 nucleus GO:0005634 9.32 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2

Biological processes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.77 CDKN2A EGFR ESR1 PGR WT1
2 positive regulation of transcription, DNA-templated GO:0045893 9.71 CDKN2A EGFR ESR1 WT1
3 negative regulation of cell proliferation GO:0008285 9.46 BAP1 CDKN2A NF2 WT1
4 cellular response to estradiol stimulus GO:0071392 9.43 EGFR ESR1
5 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.32 CDKN2A LATS2
6 negative regulation of cell-matrix adhesion GO:0001953 9.26 CDKN2A NF2
7 regulation of inflammatory response GO:0050727 9.13 BAP1 BIRC3 ESR1
8 regulation of toll-like receptor signaling pathway GO:0034121 8.62 BIRC3 ESR1

Molecular functions related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.7 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2
2 steroid binding GO:0005496 9.16 ESR1 PGR
3 nitric-oxide synthase regulator activity GO:0030235 8.62 EGFR ESR1

Sources for Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....